HCC in the Setting of Hepatitis B: Asia-Pacific Considerations

In these slides, expert faculty discusses Asia-Pacific considerations relevant to patients with HCC in the setting of hepatitis B.
Grace LH Wong, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 691 KB
Released: June 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Gilead Sciences, Inc.

Related Content

Dr Nancy Reau discusses her take on new viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Nancy Reau, MD Released: December 2, 2022

Prof George Lau: proactive monitoring and treatment are necessary for all patients with CHB, regardless of age, from Clinical Care Options (CCO)

George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA) Released: December 1, 2022

Expert summaries of AASLD, EASL, APASL guidance on monitoring and treating chronic hepatitis B and delta infections, with Maria Buti, Paul Kwo, Grace Wong

Maria Buti, MD Paul Y. Kwo, MD Grace LH Wong, MD Released: December 1, 2022

Expert summaries of AASLD, EASL, and APASL guidance on monitoring and treating chronic hepatitis B and delta viral infections, from Clinical Care Options (CCO)

Maria Buti, MD Paul Y. Kwo, MD Grace LH Wong, MD Released: December 1, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings